Alzheimer’s Trials: A Call for Mechanistic Rigor in Drug Development

Recent setbacks in clinical trials for Alzheimer’s disease, including failures of therapies targeting amyloid, tau, TREM2, and neuroinflammation, underscore a critical need to reassess the balance between clinical ambition and a deep understanding of disease mechanisms. These outcomes highlight the importance of robust mechanistic support before initiating large-scale clinical trials.

Novo Nordisk’s Semaglutide Fails to Unhurried Alzheimer’s Progression

In November 2025, Novo Nordisk announced that its oral glucagon-like peptide-1 receptor agonist (GLP-1RA), Rybelsus (semaglutide), did not significantly slow the progression of Alzheimer’s disease in the Phase III EVOKE and EVOKE+ trials Alzforum, Clinical Trials Arena. Semaglutide, the active ingredient in both Rybelsus and the weight loss drug Wegovy, showed no significant change in clinical dementia rating, sum of boxes (CDR-SB) scores compared to placebo after two years of treatment Clinical Trials Arena. Despite this, the trials did reveal improvements in Alzheimer’s-related biomarkers, though these changes were insufficient to continue development of the drug for this indication Clinical Trials Arena. Novo Nordisk has discontinued the one-year extension periods for both trials.

Johnson & Johnson’s Posdinemab Trial Also Discontinued

The failure of semaglutide coincided with Johnson & Johnson’s decision to halt its Phase 2 trial of posdinemab, a tau-targeting therapy, after it also failed to demonstrate a slowing of cognitive decline compared to placebo AlzDiscovery.

The Need for Mechanistic Sufficiency

Experts suggest that these trial failures aren’t simply due to the complexity of neurodegenerative diseases or typical pipeline issues, but may reflect a trend of testing interventions before fully understanding the underlying disease mechanisms, their timing, and relevance to specific patient populations AlzDiscovery. A shift towards prioritizing “mechanistic sufficiency” – demonstrating a clear biological rationale and human relevance – is crucial before initiating clinical trials.

Key Elements of Mechanistic Sufficiency

• Upstream of Irreversible Damage: Evidence that a therapeutic target operates before irreversible damage occurs in the brain.
• Causal Impact in Human-Relevant Systems: Demonstrating that modulating the target has a therapeutic effect in systems that accurately reflect human biology.
• Alignment of Mechanism, Biomarker, and Endpoint: Ensuring that biomarkers and clinical endpoints accurately reflect the biological process being targeted.

The Path Forward: Better Trials, Later

The consensus is that progress in Alzheimer’s disease treatment isn’t dependent on running more trials faster, but on conducting better trials, initiated at a later stage of understanding. Even negative trials can provide valuable insights if they are definitive. A shared commitment to a minimum mechanistic threshold, coupled with innovative trial designs and regulatory flexibility, will be essential to advancing the field and ultimately developing effective therapies for Alzheimer’s disease AlzDiscovery.